Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Follow-up of BGG492 in Partial Onset Seizures
NCT02150213Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of selurampanel in focal onset seizure, sponsored by Novartis. Primary endpoints: Incidence of Adrenal Cortical Adenomas and Incidence of Uterine Endometrial Stromal Sarcomas. Started Aug 2014; status: completed.
02
Drugs
selurampanel
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT02150213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150213.